The Impact of the COVID-19 Pandemic on Time to Treatment in Surgical Oncology: A National Registry Study in The Netherlands

Author:

van Vuren Roos M. G.1,Janssen Yester F.23,Hogenbirk Rianne N. M.1ORCID,de Graaff Michelle R.14,van den Hoek Rinske1ORCID,Kruijff Schelto156,Heineman David J.7,van der Plas Willemijn Y.7,Wouters Michel W. J. M.489ORCID

Affiliation:

1. Department of Surgery, University Medical Centre Groningen, 9713 GZ Groningen, The Netherlands

2. Department of Neurosurgery, University Medical Centre Groningen, 9713 GZ Groningen, The Netherlands

3. TRACER Europe B.V., Aarhusweg 2-1, 9723 JJ Groningen, The Netherlands

4. Dutch Institute for Clinical Auditing, Scientific Bureau, 2333 AA Leiden, The Netherlands

5. Department of Nuclear Medicine and Molecular Imaging, University Medical Centre Groningen, 9713 GZ Groningen, The Netherlands

6. Department of Molecular Medicine and Surgery, Karolinska Institutet, 17177 Stockholm, Sweden

7. Department of Surgery, Amsterdam UMC Location Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands

8. Department of Biomedical Data Sciences, Leiden University Medical Centre, 2333 ZA Leiden, The Netherlands

9. Department of Surgical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, 1066 CX Amsterdam, The Netherlands

Abstract

To avoid delay in oncological treatment, a 6-weeks norm for time to treatment has been agreed on in The Netherlands. However, the impact of the COVID-19 pandemic on health systems resulted in reduced capacity for regular surgical care. In this study, we investigated the impact of the COVID-19 pandemic on time to treatment in surgical oncology in The Netherlands. Methods: A population-based analysis of data derived from five surgical audits, including patients who underwent surgery for lung cancer, colorectal cancer, upper gastro-intestinal, and hepato-pancreato-biliary (HPB) malignancies, was performed. The COVID-19 cohort of 2020 was compared to the historic cohorts of 2018 and 2019. Primary endpoints were time to treatment initiation and the proportion of patients whose treatment started within 6 weeks. The secondary objective was to evaluate the differences in characteristics and tumour stage distribution between patients treated before and during the COVID-19 pandemic. Results: A total of 14,567 surgical cancer patients were included in this study, of these 3292 treatments were started during the COVID-19 pandemic. The median time to treatment decreased during the pandemic (26 vs. 27 days, p < 0.001) and the proportion of patients whose treatment started within 6 weeks increased (76% vs. 73%, p < 0.001). In a multivariate logistic regression analysis, adjusting for patient characteristics, no significant difference in post-operative outcomes between patients who started treatment before or after 6 weeks was found. Overall, the number of procedures performed per week decreased by 8.1% during the pandemic. This reduction was most profound for patients with stage I lung carcinoma and colorectal carcinoma. There were fewer patients with pulmonary comorbidities in the pandemic cohort (11% vs. 13%, p = 0.003). Conclusions: Despite pressure on the capacity of the healthcare system during the COVID-19 pandemic, a larger proportion of surgical oncological patients started treatment within six weeks, possibly due to prioritisation of cancer care and reductions in elective procedures. However, during the pandemic, a decrease in the number of surgical oncological procedures performed in The Netherlands was observed, especially for patients with stage I disease.

Funder

Dutch Organisation for knowledge and innovation in health, healthcare and well-being

Publisher

MDPI AG

Reference38 articles.

1. Lookhuyzen, L. (2023, June 08). Uitstel Kan, Maar Ook Dat Is Eindig—NRC. Available online: https://www.nrc.nl/nieuws/2020/03/26/andere-zorg-uitstellen-kan-maar-niet-oneindig-a3995039.

2. Stoffelen, A., and Huisman, C. (2023, June 08). Chemo Uitgesteld, Transplantatie Afgeblazen: In de Ziekenhuizen Voltrekt Zich Een Schaduwcrisis. Available online: https://www.volkskrant.nl/nieuws-achtergrond/chemo-uitgesteld-transplantatie-afgeblazen-in-de-ziekenhuizen-voltrekt-zich-een-schaduwcrisis~b9d4efb4/?referrer=https%3A%2F%2Fwww.google.com%2F.

3. Impact of the COVID-19 Pandemic on Surgical Care in The Netherlands;Hogenbirk;Br. J. Surg.,2022

4. Federatie Medisch Specialisten (2023, June 21). Normering Oncologische Zorg in N. SONCOS Normeringsrapport. Available online: https://demedischspecialist.nl/sites/default/files/SONCOS-normeringsrapport-versie-8-1.pdf.

5. Early Outcomes from the Dutch Upper Gastrointestinal Cancer Audit;Busweiler;Br. J. Surg.,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3